MyFinsight
Home
Blog
About
Contact
Download
Download image
Warrant inducement
offer - exercise...
$2,051,852
Private placement of
warrants
$1,999,791
Exercise of pre-funded
warrants
$210
Net cash provided by
financing activities
$3,685,235
Canceled cashflow
$366,618
Net decrease in cash
-$1,429,146
Canceled cashflow
$3,685,235
Impairment of in-process
research and development
$18,647,903
Accrued expenses and
other current...
$717,255
Accounts payable
$689,268
Issuance of common stock
pursuant to vendor...
$240,000
Stock-based compensation
$222,831
Vendor deposits
$161,927
Write-off of deferred
offering costs
$57,238
Registration and issuance
costs associated with...
$366,618
Net cash used in
operating activities
-$5,114,381
Canceled cashflow
$20,736,422
Net loss
-$24,952,378
Deferred tax (benefit)
provision
-$851,659
Prepaid expenses and
other current assets
$46,766
Back
Back
Cash Flow
source: myfinsight.com
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)